Tumorigenesis caused by the peroxisome proliferator (PP) class of non-genotoxic hepatocarcinogens is species restricted; rat and mouse are considered responsive whereas the available evidence suggests that humans, nonhuman primates, dogs, hamsters and guinea pigs are nonresponsive. We have demonstrated previously that the PP, nafenopin can suppress rat hepatocyte apoptosis both in vitro and in vivo. Here we describe the ability of nafenopin to suppress apoptosis in mouse, hamster, guinea pig and rat hepatocytes and induce S-phase in mouse and rat hepatocytes. Hepatocyte monolayers from all species examined degenerated rapidly in culture. However, nafenopin (50 uM) reversibly maintained the viability of both rat and mouse hepatocytes. This maintenance was associated with a decrease (P =£ 0.01) in the number of hepatocytes displaying chromatin condensation patterns characteristic of apoptosis. Treatment of rat and mouse monolayers with 5 ng/ml transforming growth factor-pi (TGFpi) induced high levels of apoptosis (P =£ 0.01); co-addition of nafenopin suppressed this induced apoptosis (P =e 0.01). TGFpi also induced apoptosis in hamster and guinea pig hepatocytes (P *£ 0.01) and unexpectedly nafenopin was able to suppress this induced apoptosis (P =s 0.01) as well as reversibly maintaining the viability of hamster and guinea pig hepatocyte monolayers. Thus, all the species examined responded to nafenopin by a suppression of both spontaneous and TGFpi -induced apoptosis. In contrast, only rat and mouse hepatocytes showed an induction of S-phase in response to nafenopin (P =s 0.01). Certain key experiments were repeated using the PPs methyl clofenapate (MCP) (100 uM) and Wy-14, 643 (10 JJM). Both were able to suppress spontaneous and TGFfJl-induced apoptosis in rat and guinea pig hepatocytes although the effects of MCP were weak (P « 0.05) compared with nafenopin or Wy-14 643 (P ^ 0.01). The rat and mouse liver tumour promoter, phenobarbitone (PB) was assessed also. Rat hepatocytes responded to PB with a suppression of apoptosis and an induction of S-phase (P =e 0.01). Hamster and guinea pig cells gave no response in the S-phase assay and exhibited no suppression of either spontaneous or TGFpi-induced apoptosis. Interestingly, nafenopin suppressed the apoptosis induced by the DNA damaging drugs, etoposide and hydroxyurea (P « 0.01) suggesting that PPs can impact on *Abbreviations: PP, peroxisome proliferator, TGFpi, transforming growth factor-Pi; MCP, methyl clofenapate; PB, phenobarbitone; DEHA, diethyl hexyl adipate; nafenopin, 2-methyl-2-[p-<l,2 r 3,4-tetrahydro-l-napthyl)-phenoxyl]proionic acid; Wy-14 643, [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid; EGF, epidermal growth factor, HU, hydroxyurea; BrdU, bromodeoxyuridine; DMF, dimethylformamide; PPAR, proliferator activated receptor.
Tumorigenesis caused by the peroxisome proliferator (PP) class of non-genotoxic hepatocarcinogens is species restricted; rat and mouse are considered responsive whereas the available evidence suggests that humans, nonhuman primates, dogs, hamsters and guinea pigs are nonresponsive. We have demonstrated previously that the PP, nafenopin can suppress rat hepatocyte apoptosis both in vitro and in vivo. Here we describe the ability of nafenopin to suppress apoptosis in mouse, hamster, guinea pig and rat hepatocytes and induce S-phase in mouse and rat hepatocytes. Hepatocyte monolayers from all species examined degenerated rapidly in culture. However, nafenopin (50 uM) reversibly maintained the viability of both rat and mouse hepatocytes. This maintenance was associated with a decrease (P =£ 0.01) in the number of hepatocytes displaying chromatin condensation patterns characteristic of apoptosis. Treatment of rat and mouse monolayers with 5 ng/ml transforming growth factor-pi (TGFpi) induced high levels of apoptosis (P =£ 0.01); co-addition of nafenopin suppressed this induced apoptosis (P =e 0.01). TGFpi also induced apoptosis in hamster and guinea pig hepatocytes (P *£ 0.01) and unexpectedly nafenopin was able to suppress this induced apoptosis (P =s 0.01) as well as reversibly maintaining the viability of hamster and guinea pig hepatocyte monolayers. Thus, all the species examined responded to nafenopin by a suppression of both spontaneous and TGFpi -induced apoptosis. In contrast, only rat and mouse hepatocytes showed an induction of S-phase in response to nafenopin (P =s 0.01). Certain key experiments were repeated using the PPs methyl clofenapate (MCP) (100 uM) and Wy-14, 643 (10 JJM). Both were able to suppress spontaneous and TGFfJl-induced apoptosis in rat and guinea pig hepatocytes although the effects of MCP were weak (P « 0.05) compared with nafenopin or Wy-14 643 (P ^ 0.01). The rat and mouse liver tumour promoter, phenobarbitone (PB) was assessed also. Rat hepatocytes responded to PB with a suppression of apoptosis and an induction of S-phase (P =e 0.01). Hamster and guinea pig cells gave no response in the S-phase assay and exhibited no suppression of either spontaneous or TGFpi-induced apoptosis. Interestingly, nafenopin suppressed the apoptosis induced by the DNA damaging drugs, etoposide and hydroxyurea (P « 0.01) suggesting that PPs can impact on Introduction Non-genotoxic carcinogens have the ability to cause cancer but without directly damaging DNA (1). Presumably, they perturb some aspect of cellular growth regulation (2) . One of the most widely studied classes of rodent non-genotoxic hepatocarcinogens are the peroxisome proliferators (PPs*) (3) (4) (5) . They show wide structural diversity and include pharmaceutical agents such as the hypolipidaemic drugs nafenopin, Wy-14, 643 (6,7) and methylclofenapate (MCP) (8, 9) and chemicals of industrial and environmental importance such as the plasticizer diethyl hexyl adipate (DEHA) (10) and the chlorinated solvents (11) .
The incidence of tumorigenesis caused by PPs varies depending on species, compound and dose (5, 12) ; rat and mouse are considered to be responsive species whereas the evidence available at present indicates that human, non-human primates, dogs and guinea pigs are non-responsive (5, (12) (13) (14) . In responsive species such as the rat and mouse, acute effects are seen in the liver such as peroxisome proliferation, elevated S-phase and organ enlargement followed by the development of altered cell foci, some of which progress to hepatocellular carcinoma (13) . In non-responsive species, such as guinea pig there is no liver enlargement, peroxisome proliferation or enzyme induction in vivo (15) . The hamster is partially responsive since in vivo there is some liver enlargement, enzyme induction and proliferation of peroxisomes but no induction of S-phase (15, 16) . To date, there are no cancer data for either hamster or guinea pig but, based on the absence of S-phase (15, 16) , it seems likely that these species will be refractory to the hepatocarcinogenicity of PPs. Humans appear to be non-responsive since human hepatocytes display no peroxisome proliferation or induction of S-phase in vitro and no increased incidence of hepatocarcinogenesis has been seen in patients treated with hypolipidaemic drugs (13, 14, 17, 18) .
It is probable that the elevated S-phase induced by PPs in the rat and mouse may play a role in their hepatocarcinogenicity (5, 19, 20) . However, it was proposed some time ago that liver growth is controlled by the balance between cell proliferation and cell death by apoptosis (21) (22) (23) (24) (25) . More recently, evidence has accumulated to support this hypothesis (26) (27) (28) . We have demonstrated that PPs can suppress both spontaneous and transforming growth factor pi (TGFpi) -induced rat hepatocyte apoptosis in vitro (29, 30) and can suppress basal levels of apoptosis in rat liver in vivo (31) .
Since PPs perturb both sides of the liver growth equation between mitosis and apoptosis in rat, a species susceptible to PP-induced hepatocellular carcinoma, we and others have proposed previously that both the suppression of apoptosis and the induction of mitosis play a role in subsequent hepatocarcinogenicity (21) (22) (23) (24) (25) (26) (28) (29) (30) 32) . Both may be required, but with neither alone being sufficient for carcinogenesis. To evaluate more fully this hypothesis, we conducted analyses of species differences in hepatocyte S-phase and apoptosis rate changes in the PP-responsive species rat and mouse, in the nonresponsive guinea pig and in the partially responsive hamster. Our hypothesis predicted that levels of apoptosis and S-phase would be unaffected by PPs in those species thought of as non-responsive in contrast to the changes seen previously in rat and predicted for mouse. The data obtained challenge predictions and contribute to our understanding of the roles of mitosis, apoptosis and liver homeostatic balance in nongenotoxic carcinogenesis.
Materials and methods

Materials
Nafenopin (2-methyl-2-[p-(l,2,3,4-tetrahydro-l-napthyl) -phenoxyl]proionic acid) was a gift from Ciba-Geigy, Basel, Switzerland. Phenobarbitone (PB), Wy-14, 643 ([4-chloro-6-{2,3-xylidino}-2-pyrimidinylthio]acetic acid) and methyl clofenapate (MCP) were bought from Sigma, UK, Chemsyn, USA and Lancaster Synthesis, Morecambe, UK, respectively. Tissue culture grade mouse sub-maxillary gland epidermal growth factor (EGF), native human platelet TGFpl, etoposide and hydroxyurea (HU) were purchased from Sigma, UK. Trypsin was from Gibco, UK, and fetal calf serum was from Advanced Protein Products, UK and TCS, UK. All other tissue culture reagents were purchased from Flow, UK, Gibco, UK, or Sigma, UK. Bromodeoxyuridine (BrdU) labelling reagent was from Amersham, UK , the anti-BrdU antibody was from Boehringer Mannheim, East Sussex, UK and the peroxidase-linked anti-rabbit secondary antibody was from Dako, High Wycombe, UK. Hoechst 33258 was from Molecular Probes Inc., Junction City, OR. All tissue culture plastics were from Nunc, UK.
Preparation of primary hepatocytcs
Rat, mouse, hamster and guinea pig hepatocytes were prepared by collagenase perfusion (33) . Briefly, 180-200 g male (8-10 weeks old) AJderley Park rats (Wistar derived), male (6-8 weeks old) B6C3F1 mice (Harlan Olac, UK), male 100-150 g Syrian hamsters (Harlan Olac, UK) or male 300-400 g Hartley guinea pigs (Charles Rivers, UK) were subjected to terminal anaesthesia using ether and their livers were perfused with 0.05% w/v collagenase. Digested livers were passed through a 0.125 mm gauze and the resultant cell suspension was washed and counted using a haemocytometer. viability was determined by trypan blue exclusion. All cell preparations had a viablity of 70-95% on isolation.
Culture of primary hepatocytes
Unless otherwise stated, 2X10* freshly isolated hepatocytes were seeded into 25 cm 2 flasks in 4 ml of Williams medium supplemented with 10% fetal bovine serum (heat inactivated), 10 (ig/ml insulin, 0.1 mM hydrocortisone, 2 mM L-glutamine, 100 U/ml penicillin and 100 |ig/ml streptomycin. For guinea pig hepatocytes, ascorbic acid was added to a final concentration of 340 uM. Flasks were pre-coated with rat tail collagen to aid attachment of hepatocytes. Cultures were maintained at 37°C in a humidified atmosphere and the medium was changed 4, 24 and every subsequent 48 h after seeding. 643 or PB Nafenopin, MCP, Wy-14 643 or PB were added as indicated to the medium of hepatocytes from a 400X stock solution in dimethylformamide (DMF). Concentrations of 50 |iM nafenopin, 100 |iM MCP, 10 (iM Wy-14 643 or 4 mM PB was used for all experiments unless otherwise indicated. Control flasks were treated with DMF to the same final concentration of 0.25% (v/v).
Treatment of hepatocytes with nafenopin, MCP,
Treatment of cells with TGFfiJ
TGFpl (0.25, 1 or 5 ng/ml as indicated in the figure legends) was added to the medium from a 2 Hg/ml stock solution in 4 mM HC1, 0.1% BSA. Control flasks were treated with HCI to the same final concentration of 0.1% {v/v).
Treatment of cells with etoposide or HU
Rat hepatocyte monolayers were established as described then maintained for 24 h with or without 50 nM nafenopin. Then, etoposide (10, 20 or 40 jlM 1624 from a 400X stock in DMF) or HU (1, 2 or 4 mM from a 100X stock in Williams medium) was added to the hepatocytes in the continued presence or absence of nafenopin. After 48 h, cells were fixed and stained with Hoechst 33258 for evaluation of apoptosis as described below.
Measurement of replicative DNA synthesis by BrdU staining
To assess stimulation of replicative DNA synthesis by nafenopin or PB, fresh medium with or without nafenopin or PB was added to the hepatocyte monolayers 24 h after plating. The following day, BrdU (10 (il per 0.25 ml culture medium) was added and the cultures were maintained for a further 16 h. The monolayer was then washed, fixed and made permeable in ice-cold methanol. Incorporated BrdU was localized using an anti-BrdU antibody followed by a peroxidase-linked secondary antibody and an aminoethylcarbamate substrate. Replicative DNA synthesis was measured by scoring the percentage of red nuclei in ten random fields. A total of 1000 ± 100 cells were counted per flask.
Measurement of apoptosis
We have shown previously that apoptotic hepatocytes remain attached to the monolayer and can be detected by Hoechst 33258 staining of condensed chromalin (30). To assess the affects of nafenopin, MCP, Wy-14, 643, PB and/or TGFpi on hepatocyte death by apoptosis, fresh medium with or without nafenopin, MCP, Wy-14, 643 or PB was added to the flasks 24 h after plating. A further 24 h later, all flasks were changed into serum-free conditions with or without nafenopin, MCP, Wy-14 643 or PB and left for a further 24 h. This period in serum-free conditions rendered the hepatocytes more sensitive to the effects of TGFp"l. After this 'priming' period, TGFpl was added in the continued presence or absence of nafenopin, MCP, Wy-14, 643 or PB. At 24 h after addition of TGFpl, the monolayers were fixed in ice-cold methanol/ acetic acid (3:1) for 5 min. Cells were stained with Hoechst 33258 (5 ng/ml in physiological saline) for 10 min, washed in distilled water and mounted in a solution of 20 mM citnc acid, 50 mM disodium orthophosphate and 50% glycerol to achieve optimum fluorescence. Cells were examined at a wavelength of 350-460 nm using an inverted microscope with a far UV fluorescent filter. Apoptotic cells were identified as those with brightly staining, condensed chromatin. Where one apoptotic hepatocyte had generated multiple apoptotic bodies, this was scored as one. Similarly, care was taken to score viable binucleate hepatocytes as one. A total of 1000 ± 100 cells were counted per flask in ten random fields.
Effect of Leibovitz medium on hepatocyte apoptosis
To assess the effects of tissue culture medium on the longevity of hepatocytes and their susceptibility to apoptosis, rat, hamster or guinea pig hepatocytes were cultured in Leibovitz medium or in Williams medium as described above. Leibovitz medium supplements were the same as those used in Williams but with the additional inclusion of tryptose phosphate broth (10% v/v). Briefly, hepatocytes were isolated and placed in culture then fresh Leibovitz or Williams medium with or without nafenopin was added to the flasks 24 h after plating. The medium was changed every 48 h thereafter and the cell viability observed daily. To assess the effects of Leibovitz medium on guinea pig hepatocyte apoptosis, cells were cultured in Leibovitz medium or in Williams medium as described above. Fresh Leibovitz or Williams medium with or without nafenopin was added to the flasks 24 h after plating. A further 24 h later, all flasks were changed into serum-free conditions (Williams; W-) or serum free, tryptose phosphate broth free conditions (Leibovitz; L-) with and without nafenopin and left for a further 24 h. TGFpi was added in the continued presence or absence of nafenopin for 24 h then the monolayers were fixed and assayed for apoptosis as described above.
Assessment of the effect of serum on rat or guinea pig hepatocyte apoptosis
To assess the effects of serum on the susceptibility of hepatocytes to apoptosis, guinea pig or rat hepatocytes were subjected to a standard assay for apoptosis as described above but with the inclusion of serum to Williams (W+) or Leibovitz (L+) medium throughout the experiment. Briefly, hepatocytes were isolated and placed in culture as described above. Fresh medium with or without nafenopin was added to the flasks 24 and 48 h after plating. A further 24 h later, TGFpi was added in the continued presence or absence of nafenopin. At 24 h after addition of the TGFpi, the monolayers were fixed and assayed for apoptosis as described above. Statistics Data were analysed using the Student's two-sided r-test *P « 0.05%; •*/>* 0.01%.
Results
Maintenance of hepatocyte viability by nafenopin
Primary hepatocyte cultures from mouse, hamster and guinea pig rapidly lost viability and degenerated by 5-10 days after ) and (E) show degenerating mouse, hamster and guinea pig hepatocytes, respectively, all at 6 days after seeding. In (E), the majority of the guinea pig hepatocytes have died and been replaced by fibroblasts by this time point (B), (D) and (F) show mouse, hamster and guinea pig hepatocytes, respectively, surviving in the presence of 50 nM nafenopin at 14 days after seeding. Magnification X 150. establishment ( Figure 1A , C and E). The hepatocytes from all three species lost their phase bright canalicular membranes and their regular polygonal shape and began to detach from the flask in a manner similar to that observed previously for rat hepatocytes (30). In contrast, nafenopin maintained the viability and differentiated appearance of mouse, hamster and guinea pig hepatocytes for 14 days and beyond (Figure IB, D and F). The hepatocytes in the presence of nafenopin preserved a hexagonally packed monolayer with phase bright bile canal iculi. However, the effects were reversible since the withdrawal of nafenopin resulted in the onset of degeneration (not shown) as we described previously for rat hepatocytes (30).
Effects of nafenopin on hepatocyte apoptosis
Fluorescence microscopy of Hoechst 33258-stained hepatocyte monolayers (Figure 2A and B) was used to enumerate cells with chromatin condensation patterns typical of apoptosis. Figure 3A and B demonstrate that under control conditions (serum free tissue culture medium without nafenopin) hepatocytes from rat and mouse displayed approximately 2-5% apoptosis 4 days after the initiation of culture. However, nafenopin suppressed this apoptosis (P «£ 0.01) to approximately 0.5-1.5%. In hepatocyte cultures from hamster and guinea pig the level of apoptosis in control cultures was approximately 5-6% (Figure 3C and D) . Again, nafenopin was able to suppress dramatically this apoptosis to around 0.5-2% (P *£ 0.01). Results for all four species examined were consistent in each of three independent experiments.
Effects of TGFfil on hepatocyte apoptosis
Exposure of serum-free rat, mouse, hamster or guinea pig hepatocyte cultures to 5 ng/ml TGFpi for 24 h caused a highly significant (P =£ 0.01) increase in apoptosis ( Figures 2C and  3 ). These data show that the induction of apoptosis by TGFpi over controls ranged from 1.55-(rat) to 2.75-fold (guinea pig).
1626
The TGFpl solvent, HC1, had no effect on rates of apoptosis in any species examined.
Effects of nafenopin on TGFfi]-induced hepatocyte apoptosis
We have reported previously that nafenopin can suppress TGFpi-induced apoptosis in rat hepatocytes (30). Figure 3B and D demonstrate that nafenopin was able also to suppress significantly (P =£ 0.01) TGFpi-induced apoptosis in mouse and guinea pig hepatocytes. However, in hepatocyte cultures from hamster, the suppression of TGFpi-induced apoptosis by nafenopin was equivocal (P =£ 0.05) ( Figure 3C ). To determine if nafenopin was suppressing apoptosis in the hamster, the concentration dependence of the suppression was investigated ( Figure 4A) . A clear concentration response was observed commencing at 25 |iM and peaking at 50-75 (J.M nafenopin. Beyond 100 (iM, cell rounding and detachment provided evidence of cytotoxicity (data not shown). The concentration response to TGFpl was then examined with and without 50 |iM nafenopin. Figure 4B shows a clear concentration response in the induction of hamster hepatocyte apoptosis by TGFpl. Nafenopin was able to suppress this apoptosis at all concentrations of TGFf3l examined ( Figure 4B ).
Effects of MCP or Wy-14, 643 on spontaneous and TGFfilinduced hepatocyte apoptosis
Wy-14, 643, like nafenopin, was able to suppress both spontaneous and TGFpl-induced apoptosis in both rat and guinea pig hepatocytes {P =£ 0.01) ( Figure 5 ). MCP was able to suppress TGFpl-induced apoptosis in both species (P =£ 0.05) but gave no significant effect on spontaneous apoptosis in the rat. Figure 6A demonstrates that PB, like nafenopin, was able to suppress both spontaneous and TGFpi-induced apoptosis in rat hepatocytes (P =£ 0.01). However, PB did not suppress spontaneous or TGFpi-induced apoptosis in either hamster or guinea pig hepatocytes ( Figure 6B and C) .
Effects of phenobarbitone on spontaneous and TGF$1-induced hepatocyte apoptosis
Effects of nafenopin and phenobarbitone on hepatocyte S-phase
BrdU incorporation was used to assess rates of replicative DNA synthesis in hepatocyte monolayers ( Figure 2E and F) . 1627 As reported previously by ourselves and others (34-37), both nafenopin and PB were able to stimulate replicative DNA synthesis in rat and mouse but not in guinea pig or hamster hepatocyte monolayers (Table I) .
Effects of nafenopin on apoptosis induced by DNA-damaging agents
Treatment of rat hepatocytes with 40 nM etoposide or with 4 mM hydroxyurea caused a large induction of apoptosis over control cultures (Figure 7 ). Although we found that these concentrations of DNA-damaging drugs were optimal for inducing apoptosis, they were unable to induce the levels of apoptosis seen with TGF(3l. As with TGF(il -induced apoptosis, nafenopin suppressed dramatically the etoposide-induced and the hydroxyurea-induced apoptosis ( Figure 7 due to the relatively low levels of apoptosis induced at U|ese reduced concentrations of DNA-damaging drugs (data not shown).
Effects of Leibovitz medium or the inclusion of serum on longevity and on spontaneous or TGF$1-induced hepatocyte apoptosis
To confirm our findings using other media, several key experiments were repeated using Leibovitz medium rather than Williams medium and/or with the inclusion of serum throughout. The use of Leibovitz medium made no difference to the longevity of rat, mouse or hamster hepatocytes in culture: control hepatocytes degenerated rapidly whereas those cultured 'Percentage of hepatocytes with red nuclei in ten random fields. A total of 1000 ± 100 cells were counted per flask. **/> =£ 0.01, significantly different from control. in the presence of nafenopin maintained their viability and differentiated appearance (data not shown). However, guinea pig hepatocytes cultured in Leibovitz medium were able to survive for several weeks either in the presence or absence of nafenopin. A standard apoptosis assay was carried out on guinea pig hepatocytes using either Leibovitz or Williams medium in a direct comparison. As predicted by the longevity, spontaneous guinea pig hepatocyte apoptosis was considerably less frequent in Leibovitz medium ( Figure 8C ) compared with Williams ( Figure 8A ). However, TGFpl still was able to induce apoptosis in guinea pig hepatocytes maintained in Leibovitz medium and nafenopin was able to suppress both the spontaneous and TGF{}1 -induced apoptosis ( Figure 8C ). To assess further the effects of medium composition, a standard apoptosis assay was carried out on guinea pig hepatocytes using Leibovitz or Williams medium with the inclusion of serum (Figure 8B and D) . The inclusion of serum had no significant effect on rates of apoptosis measured in either Williams or Leibovitz medium.
Discussion
We and others have proposed previously that the hepatocarcinogenicity of PPs in the rat is due to both the stimulation of mitosis and the suppression of apoptosis (21) (22) (23) (24) (25) (28) (29) (30) 32) . Tumorigenesis caused by the PP class of non-genotoxic hepatocarcinogens is species restricted; rat and mouse are considered responsive whereas the available evidence suggests that humans, non-human primates, dogs, hamsters and guinea pigs are non-responsive (5, 12, 13) . To evaluate more fully the hypothesis that suppression of apoptosis plays a key role in non-genotoxic hepatocarcinogenesis, we analysed species differences in suppression of apoptosis by the PP, nafenopin in vitro. As predicted, nafenopin was able to suppress both spontaneous and TGFP 1 induced hepatocyte apoptosis in the rat and mouse. However, we were surprised to note a comparable suppression of apoptosis in hepatocytes from the 'non-responsive' guinea pig. Similarly, we predicted no suppression of apoptosis in hamster hepatocytes since it is considered nonresponsive in terms of liver growth and S-phase but not in terms of peroxisome proliferation. Initially, the data appeared equivocal but more extensive investigation revealed a clear suppression of both spontaneous and TGFpl induced apoptosis in hamster hepatocytes. Analyses of S-phase induction by nafenopin confirmed previously published literature: rat and mouse hepatocytes responded whereas those from hamster and guinea pig did not.
To extend our observations to other PPs, the ability of the PPs Wy-l4, 643 (6,7) and methylclofenapate (MCP) (8, 9) to suppress rat and guinea pig hepatocyte apoptosis was studied. Wy-l4, 643, another potent hepatocarcinogen and activator of the peroxisome proliferator activated receptor (PPAR) (38) , gave results comparable to those for nafenopin. MCP was less active despite being a potent rat carcinogen (8, 9) . However, this perhaps was not surprising since MCP has been reported to be less potent than nafenopin and Wy-l4, 643 in other in vitro systems such as the assay for PPAR activation (38) , perhaps reflecting its limited solubility.
The suppression of apoptosis in hamster and guinea pig hepatocytes by PPs in vitro is surprising since it implies an uncoupling of the induction of DNA synthesis from the suppression of apoptosis (Figure 9 ). In addition, the observed suppression of apoptosis in vitro must be put in context with a lack of increase in guinea pig liver weight during dosing with PPs in vivo (15, 37, 39) and a slight increase in liver weight in hamster, which has been attributed to hypertrophy 1630 rather than hyperplasia (15, 16) . One way in which these data can be reconciled is if the suppression of apoptosis in the guinea pig is offset by a parallel suppression of S-phase and mitosis ( Figure 9 ). We did not observe reduced rates of S-phase in guinea pig hepatocytes, but it is unlikely that such a homeostatic mechanism for regulation of organ size would operate in vitro. It remains to be determined if in 'nonresponsive' species such as hamster and guinea pig, some form of homeostatic mechanism can trigger a parallel suppression of S-phase serving to maintain liver weight and prevent the hyperplastic changes associated with non-genotoxic hepatocarcinogenesis. However, the only published data on S-phase for hamster or guinea pig in response to PPs, reports no change in hamster liver S-phase after dosing with nafenopin (16) .
To understand more fully our observations, S-phase and apoptosis were analysed in vitro in response to the nongenotoxic rat liver tumour promoter, phenobarbitone (PB) (40, 41) . PB causes liver enzyme induction, hyperplasia and enlargement in the rat (41, 42) but only enzyme induction in the guinea pig and no liver weight changes (37) . Unlike the response to PPs, the response of hepatocytes from different species to PB in vitro was as predicted from previous data on species differences in vivo. We found both a suppression of apoptosis and an induction of S-phase in the rat whereas no induction of S-phase and no suppression of apoptosis were seen in either hamster or guinea pig.
We have reported previously that nafenopin can suppress both spontaneous and TGFpl-induced apoptosis in the welldifferentiated rat hepatoma line, FaO but was unable to suppress apoptosis induced in FaO cells by the DNA damaging drugs, etoposide and hydroxyurea (30). This led us to speculate that the ability of nafenopin to suppress apoptosis was dependent on the nature of the apoptotic stimulus (30). However, we have found now that nafenopin can rescue cells from the apoptosis induced by DNA damage in primary rat hepatocytes. These data suggest that nafenopin is able to impinge both on the p5 3-dependent pathway for triggering apoptosis after DNA damage (43) and on the pl6 IN4B /p27 Kipl signalling pathway implicated in the arrest of the cell cycle and the triggering of apoptosis by TGFpi (44, 45) . The differing response of FaO hepatoma cells and primary rat hepatocytes may be due to the loss of some component of the DNA damage-induced signalling pathway in the FaO cell line. Comparison of suppression of apoptosis in FaO and rat hepatocytes will provide a useful experimental model for the analysis of signalling in PPsuppressed apoptosis.
Although recent data on TGFpl and the cell cycle allows for some speculation on perturbation of apoptosis by PPs, the upstream mechanisms whereby PPs may affect hepatocyte growth control are at present unknown. However, PPs are known to activate PPAR, a receptor originally cloned from mouse liver (38) . Following the isolation of this prototype PPARa, three other isoforms known as p, y and 5 have been identified (46) (47) (48) . These different isoforms of the PPAR have different tissue distributions in different species, perhaps providing clues as to their function. In species susceptible to PP-induced non-genotoxic hepatocarcinogenesis such as the mouse, PPARa is found predominantly in the liver and kidney (48) , suggesting that this isoform is involved in peroxisome proliferation, enzyme induction and hepatocarcinogenesis. Thus, activation of rat and mouse PPARa may be the trigger for the elevated mitosis and suppressed apoptosis in these species. In support of this, no peroxisome proliferation, enzyme induction or liver enlargement was reported after PP treatment of a transgenic mouse line created recently in which the PPARa gene has been deleted (49) . To date, nothing is known of PPARa expression in either hamster or guinea pig, making it difficult to speculate on how PPARa activation may be involved in the suppression of apoptosis in the absence of S-phase induction. However, PPARa displays a different tissue distribution in humans to that seen in the mouse since there is little expression in the human liver (50). This reduced expression of PPARa in human liver may extend to hamster and guinea pig, correlating with a lack of response in terms of S-phase induction and liver enlargement and the postulated lack of hepatocarcinogenesis (5, 12, 13) .
Since Leibovitz rather than Williams medium is used by some authors in studies of the effects of PPs on hepatocytes (51), certain key experiments were repeated to confirm that our findings were not media dependent. This change in medium had no effect on the longevity of rat, mouse or hamster hepatocytes in vitro since control hepatocytes rapidly degenerated whereas hepatocytes cultured in the presence of nafenopin maintained their viability and differentiated phenotype. However, we were surprised to note that guinea pig hepatocytes were able to maintain viability in Leibovitz medium even in the absence of nafenopin. This confirmed observations made previously by Plant and Elcombe (personal communication). Assessments of apoptosis for guinea pig hepatocytes confirmed the longevity data; rates of apoptosis for guinea pig hepatocytes were reduced considerably in Leibovitz medium. However, nafenopin could reduce both spontaneous and TGFfil-induced apoptosis in Leibovitz medium. In addition, the inclusion of serum to either the Williams or Leibovitz systems had no effect on the results. These data confirm the conclusions drawn from our in vitro model system. The question of why a survival advantage is conferred on guinea pig hepatocytes alone by Leibovitz medium is as yet unresolved.
In summary, the data demonstrate that species differences in the suppression of hepatocyte apoptosis by PPs do not correlate with the reported species differences in other responses to PPs such as induction of S-phase and liver enlargement ( Figure 9 ). These observations question the role of the suppression of apoptosis in PP-induced hepatocarcinogenesis. At present, two possible explanations suggest themselves; either suppression of apoptosis is required for carcinogenesis but is insufficient in the absence of a stimulation of S-phase. Alternatively, the suppression of apoptosis may be a minor factor in carcinogenesis, which may be dictated predominantly by the induction of S-phase. In responsive species such as rat and mouse, PPs stimulate S-phase and suppress apoptosis, which may swamp any homeostatic mechanism thus leading to liver enlargement and hepatocarcinogenesis ( Figure 9 ). In contrast, guinea pigs and hamsters may maintain a constant liver cellularity even when apoptosis is suppressed, perhaps by a parallel suppression of S-phase preventing subsequent hepatocarcinogenesis. We have yet to determine whether PPs can suppress apoptosis in human hepatocytes, but in the absence of a mitogenic response (14, 18) , the evidence to date continues to support the conclusion that humans are non-responsive to PPs in terms of liver enlargement and hepatocarcinogenesis. The data presented further our knowledge of'the mechanisms of species differences in nongenotoxic hepatocarcinogenesis and raise many fascinating questions on the role of apoptosis and its interplay with mitosis in carcinogenesis.
